Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

Author's Avatar
Jun 16, 2023

Takeda (TSE%3A4502%2FNYSE%3ATAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) were published in The Lancet.